Exscientia plc

NasdaqGS:EXAI Rapport sur les actions

Capitalisation boursière : US$633.4m

Exscientia Gestion

Gestion contrôle des critères 1/4

Exscientia's CEO is Dave Hallett, appointed in Feb 2023, has a tenure of 1.75 years. directly owns 0.001% of the company’s shares, worth $7.35K. The average tenure of the management team and the board of directors is 1.8 years and 3.9 years respectively.

Informations clés

Dave Hallett

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur général1.8yrs
Propriété du PDG0.001%
Durée moyenne d'occupation des postes de direction1.8yrs
Durée moyenne du mandat des membres du conseil d'administration3.9yrs

Mises à jour récentes de la gestion

Recent updates

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Aug 08

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

Jul 17
Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

Exscientia: Too Much Pessimism

Jun 10

Exscientia: Drug Discovery Platform Attracting Partners And Cash

May 22

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Feb 26

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Jan 11
Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 12
Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Aug 31
New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Aug 25
We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Jul 21
Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Apr 22
Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Dec 30
We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Aug 31
The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Exscientia: Using AI To Power Drug Development

Aug 15

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

May 29
Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline

Apr 12

Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts

Jan 09
Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts

PDG

Dave Hallett (55 yo)

1.8yrs

Titularisation

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...


Équipe de direction

NomPositionTitularisationCompensationPropriété
David Hallett
Chief Scientific Officer1.8yrspas de données0.0012%
$ 7.3k
Ben Taylor
CFO, Chief Strategy Officer & Executive Director4yrsUK£1.92m0.062%
$ 392.2k
John Overington
Chief Technology Officerless than a yearpas de données0.015%
$ 96.0k
Sara Sherman
Vice President of Investor Relationsno datapas de donnéespas de données
Dan Ireland
Executive VP of Legal & Company Secretary1.8yrspas de donnéespas de données
Parker Moss
Executive Vice President of Corporate Developmentless than a yearpas de donnéespas de données
Caroline Rowland
Chief People Officer2.2yrspas de donnéespas de données
Richard Law
Chief Business Officerno datapas de donnéespas de données
Nikolaus Krall
Executive Vice President of Precision Medicine1.8yrspas de donnéespas de données
Marie-Louise Fjallskog
Interim Chief Medical Officer & Clinical Development Leadless than a yearpas de donnéespas de données

1.8yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: EXAI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Hallett
Chief Scientific Officerless than a yearpas de données0.0012%
$ 7.3k
Ben Taylor
CFO, Chief Strategy Officer & Executive Director4yrsUK£1.92m0.062%
$ 392.2k
Elizabeth Crain
Independent Non-Executive Chairman3.8yrsUK£282.03k0.089%
$ 564.4k
Mario Polywka
Independent Non-Executive Director7.2yrsUK£201.69k0.053%
$ 334.4k
Robert Ghenchev
Independent Non-Executive Director4.5yrspas de donnéespas de données
Franziska Michor
Independent Director1.5yrsUK£178.86k0.028%
$ 177.9k

3.9yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Conseil d'administration expérimenté: EXAI's board of directors are considered experienced (3.9 years average tenure).